The QUARTET Project (Quality and Excellence in Radiotherapy and Imaging for Children and Adolescents with Cancer across Europe in Clinical Trials) is an established collaboration between SIOPE and EORTC that aims to improve radiotherapy treatments for children and adolescents by reducing the risk of local recurrence and increasing cure rates for children treated for cancer, in addition to minimising long term treatment-related side effects and maximising the quality of life for survivors.

Improving the effectiveness of radiotherapy has an important role in achieving better outcomes for childhood cancer patients. To achieve this the QUARTET group is evaluating the effectiveness of radiotherapy in paediatric, teenage and young adult (TYA) cancers through an online prospective quality assurance programme, set up in partnership with EORTC. QUARTET offers prospective centralised review of radiotherapy delineations and treatment plans for every child and TYA treated in clinical trials, allowing necessary amendments to be made prior to treatment delivery.

QUARTET has been funded thanks to the generosity of Fondatioun Kriibskrank Kanner, a Luxembourg foundation that provides multi-disciplinary support to families of children with cancer, raises awareness to improve the condition of sick children and actively supports paediatric oncology research with one goal: heal better and quicker.


QUARTET officially launched in 2016 and now has 16 projects in its portfolio; spanning all major tumour types affecting children and adolescents. These projects include retrospective RTQA analyses, prospective RTQA delivery, and both retrospective and prospective imaging studies. QUARTET currently delivers prospective RTQA for children and TYAs treated in prospective clinical trials for neuroblastoma, rhabdomyosarcoma, and brain tumours, and continues to expand as new trials come on board. More specifically, the project:

  • Uses the EORTC radiotherapy quality assurance platform to deliver customised RTQA programs
  • Provides expert paediatric radiation oncologists and physicists to support the RTQA program development and delivery for clinical trials implemented within the SIOPE community
  • Operates in collaboration with the SIOPE Radiation Oncology Working Group
  • Tracks all real-time quality control data;
  • Conducts research projects.



The QUARTET project offers a one-year research fellowship (renewable to a maximum of 3 years subject to funding) with the following objectives:

  1. Development of standards for quality control of radiotherapy for paediatric & TYA tumours in Europe.
  2. Evaluate the role and benefit of implementing a benchmark case exercise as part of site approval procedures.
  3. To co-ordinate and participate in the assessment of the quality of the radiotherapy delivered; looking to determine whether geographical location or treatment centre size (number of patients) have any impact on this.
  4. To assess the cost-effectiveness of quality assurance for radiotherapy planned for the prospective studies, looking to evaluate the costs and benefits for implementation of RTQA for the respective cancer types, and determining the role for RTQA for future trials.
  5. To report to trial sponsors and study leads regarding the progress and outcomes of the RTQA program(s).
  6. Research into novel radiotherapy treatment schemes or techniques that may increase therapeutic benefit and decrease toxicity risks, including proton therapy and brachytherapy.
  7. Validation of the concept of prospective quality review in radiotherapy.
  8. Potential to register for PhD if agreement to extend post up to 3 years.

You will work closely with one other research fellow dedicated to QUARTET.



  • A radiation oncologist in training (for a minimum of 3 years) or other health care professional with experience in radiotherapy planning and dosimetry.
  • Experience in radiotherapy techniques with an interest in paediatric radiation oncology and clinical trials.
  • Statistical skills are an asset.
  • Ability to work independently, under supervision of the radiation oncologists of the QUARTET steering group and its chair.
  • Excellent oral and written communication skills (in English).
  • Have an interest in research methodology and good research practices in radiation oncology.
  • Good understanding of and skills in data management
  • Excellent organisation skills
  • Be motivated and have a strong sense of responsibility.
  • Ability and interest to write peer-reviewed articles and grants, and to present in scientific conferences.
  • Be a team player.
  • Be able to work in an international and multidisciplinary environment.
  • Be under 40 years of age.

A letter of motivation must be sent along with Curriculum Vitae, containing the following information:

  • Full name
  • Gender
  • Date of birth
  • Nationality
  • Permanent and current address
  • Phone number
  • E-mail address
  • Level of all known languages: Reading/Writing/Speaking – Fluent/Good/Some
  • Academic background since secondary school
  • Professional qualifications and experience, especially in paediatric radiotherapy and clinical trials (please mention addresses)
  • Experience with treatment planning systems
  • Current position (please mention address)
  • Date of availability
  • A list of abstracts / publications
  • Three referees and their contact information
  • Two letters of recommendation


All documents should be written in English.

Support to the fellow is provided by a multidisciplinary staff including medical doctors and physicists. The fellowship will take place at the EORTC Headquarters in Brussels, Belgium, where SIOPE also has its office, although there may be scope for some component of remote virtual working.

The fellowship starting date is in 2021. The fellowship is for a period of one year, renewable to a maximum of 3 years subject to funding. EORTC and SIOPE offer a highly stimulating, professional and friendly atmosphere in an international environment.

Please send your Curriculum Vitae, a letter of intent and two letters of recommendation via e-mail no later than 15 June 2021 to